• by bcarlson@marketresearch.com
  • October 14 2014


Ebola Threat Leads To Fast Track Vaccine Efforts

Ebola Threat Leads To Fast Track Vaccine Efforts

Companies who had vaccine programs for Ebola are speeding them up in the wake of the focus on this disease.  Many concerns are aligning with the WHO’s Ebola Response Roadmap, including its call to fast-track access to treatment and vaccine options to address the urgent situation.  Kalorama covers the vaccine market including future forecasts in its recent report on the industry.  

The Ebola outbreak in Western Africa is mobilizing international health organizations, both public and private, across the globe, and with good reason. Nearly 40% of the total number of reported cases have occurred within the past three weeks and Ebola has a mortality rate ranging from 50% to 90% according to the World Health Organization (WHO).

Two candidate vaccines have clinical-grade vials available for phase 1 pre-licensure clinical trials. One, cAd3-ZEBOV, has been developed by GlaxoSmithKline in collaboration with the US National Institute of Allergy and Infectious Diseases (NIAID), part of National Institutes of Health (NIH). The second, rVSV-ZEBOV, was developed by the Public Health Agency of Canada in Winnipeg. The license for commercialization of the Canadian vaccine is held by an American company, the NewLink Genetics company.

Johnson & Johnson is fast-tracking the development of a promising new combination vaccine regimen featuring components that are based on AdVac® technology from Crucell N.V. (part of the Janssen pharmaceutical companies of Johnson & Johnson, based in the Netherlands) and the MVA-BN® technology from Bavarian Nordic (a biotech company, based in Denmark). The program has received direct funding and is also utilizing vaccine preclinical services from the NIAID. This development program will be brought forward for initiation of a clinical trial of this combined regimen in humans in early 2015.

 

The gravity of this situation is forcing events to move more quickly than the norm. The WHO estimates that it generally takes at least 10 years for new vaccine products to drop enough in price to reach developing nations. As a result, developing nations have not benefited as much from the introduction of vaccines. Kalorama discusses this and other issues of vaccine production and delivery in detail in Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments.

Developing nations have tended to experience greater medical need than ability to pay for vaccines, therefore suffering from chronic shortages of all types of medicines, including vaccines. Historically there has been a 15 to 20 year gap between access to a new vaccine in developed countries and resource-poor countries, due mainly to the inability of developing nations to pay similar prices as developed countries. This is important due to the very high costs (reaching $500 million or more) of commercializing new vaccines and the resulting need of vaccine producers to re-coup their investment.

 

This is changing, however; initiatives to introduce newer products such as vaccines to the developing countries in shorter timeframes have been introduced.  Vaccine bonds were pioneered by The International Finance Facility for Immunisation (IFFIm), a 10-year initiative created in 2006 to raise capital for Alliance for Vaccines and Immunization (GAVI) through the sale of bonds on the open market. Launched in 2000 at the annual meeting of the World Economic Forum in Davos, GAVI is comprised of developing country and donor governments, the WHO, UNICEF, the World Bank, various vaccine developers as well as the Bill & Melinda Gates Foundation, with a mission of providing vaccination to the developing world. It is estimated that more than 2.3 million early deaths were prevented as a result of support by GAVI in its first six years of operation.

 

Nonetheless, significant delays still exist in getting many vaccines to developing nations. In the case of the Ebola outbreak, the WHO’s Ebola Response Roadmap has called for fast-track access to treatment and vaccine options to address the virus outbreak, which has a number of unprecedented dimensions. The Roadmap is sufficiently flexible to accommodate rapid changes in the outbreak’s epidemiology and the needs this creates.

This acute problem reinforces the general importance of vaccines, which protect not only individuals but also entire communities from diseases spread by person-to-person transmission. Interest in the global vaccine market is therefore high.Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segmentsinvestigates the changes vaccine manufacturers have undergone in the past year, providing world market analysis, identifying the key players, and outlining critical trends in this fast-changing industry. The report examines the global market for vaccines, covering specifically commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable.

Information onVaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segmentscan be found at KI:http://www.kaloramainformation.com/Vaccines-Key-Players-8120410/.